Chan-Gyu Lee
Corporate Officer/Principal presso EUBIOLOGICS CO., LTD.
Patrimonio netto: 513 545 $ in data 31/05/2024
Provenienza dei contatti di primo grado di Chan-Gyu Lee
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 10 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Chan-Gyu Lee tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| JPMORGAN CHASE & CO. | Major Banks | Private Equity Investor | |
| Kingsborough Community College | College/University | Director/Board Member | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
Korea Investment Partners Co., Ltd.
 Korea Investment Partners Co., Ltd. Investment ManagersFinance Korea Investment Partners Co., Ltd(Korea Investment Partners). is a Private Equity/Venture Capital firm, a subsidiary of Korea Investment Holdings Co., Ltd. founded in 1986. Korea Investment Partners Co., Ltd. is headquartered in Seoul. | Investment Managers | Private Equity Investor | |
| Seoul National University | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
| Inha University | College/University | Doctorate Degree | |
| Hanyang University | College/University | Undergraduate Degree | |
| Korea University | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Jewon Accounting Corp.
 Jewon Accounting Corp. Miscellaneous Commercial ServicesCommercial Services Jewon Accounting Corp. is a South Korean company. | Miscellaneous Commercial Services | Director/Board Member | |
| Sogang University | College/University | Masters Business Admin | |
CKD Venture Capital Corp.
 CKD Venture Capital Corp. Investment ManagersFinance CKD Venture Capital Corp. a venture capital subsidiary of ChongKunDang Holdings Corp. founded in 1997. CKD Venture Capital Corp. is headquartered in Seoul, South Korea. | Investment Managers | Private Equity Analyst | |
| Korea Institute of Industrial Technology Evaluation & Plng | Director/Board Member | ||
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
Kyung Hee University
 Kyung Hee University Other Consumer ServicesConsumer Services Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea. | College/University | Undergraduate Degree | |
Sartorius Korea Biotech Co., Ltd.
 Sartorius Korea Biotech Co., Ltd. Engineering & ConstructionIndustrial Services Part of Sartorius AG, Sartorius Korea Biotech Co., Ltd. is a South Korean company that provides engineering services. The company is based in Seongnam, South Korea. The company was founded in 2005. Duk-Sang Kim has been the CEO of the company since 2005. | Engineering & Construction | Chief Executive Officer | |
InDevR, Inc.
 InDevR, Inc. Medical SpecialtiesHealth Technology InDevR, Inc. develops and delivers analytical tools for detection and characterization of biological molecules and microorganisms. The firm offers on the ampliPHOX Colorimetric Detection platform and Custom Arrays to enable its customers a low risk means to explore the high utility of focused microarrays. The company was founded by Kathy L. Rowlen, Laura Kuck and John W. Birks in 2003 and is headquartered in Boulder, CO. | Medical Specialties | Director/Board Member | |
| Woodrow Wilson School of Public & International Affairs | College/University | Undergraduate Degree | |
Global Health Investment Fund
 Global Health Investment Fund Investment ManagersFinance Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements. | Investment Managers | Private Equity Investor | |
| Global Health Investment Corp. | Corporate Secretary | ||
LHGP Asset Management LLP (Private Equity)
 LHGP Asset Management LLP (Private Equity) Investment ManagersFinance LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom. | Investment Managers | Private Equity Investor | |
| Korea Biotechnology Commercialization Center | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | ||
Codagenix, Inc.
 Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Medical/Nursing Services | Director/Board Member | |
| PLUMBLINE LIFE SCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Univercells SA
 Univercells SA BiotechnologyHealth Technology Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium. | Biotechnology | Director/Board Member | |
X-Vax Technology, Inc.
 X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| MOM'S TOUCH&CO. | Restaurants | Chief Executive Officer | |
IanTech, Inc.
 IanTech, Inc. Medical SpecialtiesHealth Technology IanTech, Inc. develops ophthalmic devices for cataract surgery. Its products include miLoop, miPhaco, miMissions, and miResources. The company was founded by Luke Clauson and Sean Ianchulev and is headquartered in Reno, NV. | Medical Specialties | Director/Board Member | |
Adjuvant Capital LP
 Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Investment Managers | Founder | |
VitriVax, Inc.
 VitriVax, Inc. BiotechnologyHealth Technology VitriVax, Inc. is a biotechnology company based in Boulder, CO that partners with vaccine developers to create thermostable vaccines that can be delivered in a single shot. The company's proprietary atomic layering thermostable antigen and adjuvant (alta™) technology platform enables vaccines to be shipped ly without refrigeration or freezing, last for years on the shelf, and only require one patient interaction to deliver multiple doses. The alta™ technology can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses and additional booster doses in a single-shot administration. The company was founded by Robert Garcea and Theodore Randolph, and the CEO is Matthew Raider. | Biotechnology | Director/Board Member | |
| Right Fund | Director/Board Member |
Statistiche
Distribuzione geografica
| Corea del Sud | 16 |
| Stati Uniti | 12 |
| Regno Unito | 3 |
| Austria | 2 |
| Belgio | 2 |
Settori
| Consumer Services | 11 |
| Health Technology | 8 |
| Finance | 7 |
| Health Services | 3 |
| Commercial Services | 2 |
Posizioni
| Director/Board Member | 23 |
| Undergraduate Degree | 8 |
| Private Equity Investor | 5 |
| Corporate Officer/Principal | 5 |
| Doctorate Degree | 4 |
Contatti più connessi
- Borsa valori
- Insiders
- Chan-Gyu Lee
- Connessioni Società
